KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Change in Cash (2016 - 2025)

Historic Change in Cash for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $1.8 billion.

  • Novartis Ag's Change in Cash rose 20038.13% to $1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$600.0 million, marking a year-over-year increase of 6332.52%. This contributed to the annual value of -$600.0 million for FY2025, which is 6332.52% up from last year.
  • Latest data reveals that Novartis Ag reported Change in Cash of $1.8 billion as of Q4 2025, which was up 20038.13% from $2.9 billion recorded in Q3 2025.
  • Novartis Ag's 5-year Change in Cash high stood at $5.5 billion for Q3 2024, and its period low was -$10.2 billion during Q2 2022.
  • Its 5-year average for Change in Cash is $84.8 million, with a median of $735.0 million in 2021.
  • As far as peak fluctuations go, Novartis Ag's Change in Cash skyrocketed by 94337.35% in 2021, and later tumbled by 112000.0% in 2024.
  • Novartis Ag's Change in Cash (Quarter) stood at $5.2 billion in 2021, then crashed by 125.98% to -$1.4 billion in 2022, then soared by 113.33% to $180.0 million in 2023, then crashed by 1120.0% to -$1.8 billion in 2024, then surged by 200.38% to $1.8 billion in 2025.
  • Its Change in Cash stands at $1.8 billion for Q4 2025, versus $2.9 billion for Q3 2025 and -$792.0 million for Q2 2025.